Great Lakes Advisors’s Heron Therapeutics HRTX Stock Holding History

Great Lakes Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15,380	Closed	-$88K	–	703
2022 Q1	$88K	Hold	15,380	–	–	﹤0.01%	694
2021 Q4	$140K	Sell	15,380 -777,776	-98%	-$7.94M	﹤0.01%	683
2021 Q3	$8.48M	Buy	793,156 +70,178	+10%	+$854K	0.13%	199
2021 Q2	$11.2M	Buy	+722,978	New	+$11.5M	0.17%	178
2020 Q1	–	Sell	-259,247	Closed	-$6.09M	–	556
2019 Q4	$6.09M	Buy	259,247 +1,046	+0.4%	+$23.1K	0.13%	195
2019 Q3	$4.78M	Buy	+258,201	New	+$4.75M	0.1%	218

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Great Lakes Advisors's HRTX Position: Q2 2022 in Review

Great Lakes Advisors sold out of Heron Therapeutics (HRTX) in Q2 2022, closing a stake of 15,380 shares — an estimated $88K sold.

Great Lakes Advisors first reported a position in HRTX in Q3 2019 and held it in 6 quarters. The position peaked at $11.2M in Q2 2021. 174 funds tracked by Wall St. Rank hold HRTX as of Q2 2022.

Great Lakes Advisors reported no remaining Heron Therapeutics position as of Q2 2022 after selling out during the quarter.
Great Lakes Advisors sold 15,380 Heron Therapeutics shares in Q2 2022, an estimated $88K.
Great Lakes Advisors first reported a position in Heron Therapeutics in Q3 2019 and held it in 6 quarters.
Great Lakes Advisors's Heron Therapeutics position peaked at $11.2M in Q2 2021.
174 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2022.

Based on Great Lakes Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.